Personalis develops and commercializes cancer genomic testing services through a CLIA-certified laboratory, offering a suite of tumor-profiling and liquid biopsy tests designed to identify actionable mutations, detect minimal residual disease, and guide therapy selection for cancer patients and biopharmaceutical companies. The company generates revenue by providing clinical testing services to oncologists and cancer centers, research and biomarker services to pharmaceutical and biopharmaceutical firms conducting clinical trials and drug development, and sequencing services to diagnostic companies and research institutions. Personalis serves global customers including major pharmaceutical companies, diagnostics providers, universities, and government entities, with primary revenue concentration in North America, and pursues adoption through clinical evidence generation and insurance reimbursement coverage.